Premium
Practical aspects of 3,4‐diaminopyridine treatment of the Lambert‐Eaton myasthenic syndrome
Author(s) -
Lundh H.,
Nilsson O.,
Rosén I.,
Johansson S.
Publication year - 1993
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1993.tb04205.x
Subject(s) - lambert eaton myasthenic syndrome , repetitive nerve stimulation , pyridostigmine , myasthenia gravis , medicine , neuromuscular transmission , compound muscle action potential , adverse effect , pyridostigmine bromide , anesthesia , electrophysiology
3,4‐Diaminopyridine (3,4‐DAP) given alone or combined with pyridostigmine is the recommended basic therapy in the Lambert‐Eaton myasthenic syndrome (LEMS). We present and exemplify our routine test protocol for monitoring drug introduction and treatment regimen of cholinergic drugs in LEMS. The individual drug responses vary and no recommended standard doses exist. Routine electrophysiological repetitive nerve stimulation studies recording amplitude of initial compound muscle action potential (CMAP) in thenar muscles correlate excellently with clinical myasthenic muscle power tests in clinically affected muscle groups. Therefore repetitive clinical muscle power tests, that often are complicated by painful myalgia and activation potentiation, can be replaced by recordings of CMAP in the introduction and clinical follow up of cholinergic drug treatment in LEMS. Also, adverse effects and other treatment problems from the experience of continuous treatment of 19 LEMS patients with 3,4‐DAP for up to 10 years are presented.